CELLTRION
24.5.2024 03:27:31 CEST | Business Wire | Press release
Celltrion today announced that the European Commission (EC) has approved Omlyclo® (CT-P39), an omalizumab biosimilar referencing Xolair®. Omlyclo® is approved for the treatment of allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP).
The EC approval of Omlyclo® follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in March 2024.
The decision is based on clinical evidence, including results from a global Phase III clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of Omlyclo® compared to the reference product Xolair® in patients with CSU up to Week 40.
“For more than two decades, omalizumab, a blockbuster monoclonal antibody anti-IgE, has revolutionised the management of chronic immune-mediated inflammatory diseases,” said Professor Marcus Maurer, Professor of Dermatology and Allergy, Co-Director for the Fraunhofer Site for Immunology and Allergology of the Fraunhofer Translational Medicine and Pharmacology ITMP and Executive Director for the Institute of Allergology, Charité - Universitätsmedizin Berlin, Germany. “The development of a biosimilar of omalizumab is a welcome solution to help alleviate some challenges with treatment access. The recently approved treatment Omlyclo® has a comparable efficacy, safety and immunogenicity profile to Xolair®.”
“Immunological conditions such as asthma can have a significant impact on the day-to-day lives of patients without appropriate treatment and care. This is why we are pleased to receive the first EC approval for an omalizumab biosimilar in Europe, an important step towards improving patient access to treatment. As we continue to expand our biosimilar offerings across the globe, building on our immunology and oncology product portfolio, we look forward to making a meaningful difference for patients living with immunological conditions,” said Hyoung-Ki Kim, Vice Chairman at Celltrion.
Omlyclo® is Celltrion’s sixth biosimilar, besides Remsima® SC, a subcutaneous formulation of infliximab, approved for use in the EU, following the approval of Remsima® (biosimilar infliximab), Truxima® (biosimilar rituximab), Herzuma® (biosimilar trastuzumab), Yuflyma® (biosimilar adalimumab), and Vegzelma® (biosimilar bevacizumab). Omlyclo® is currently under review by the U.S. Food and Drug Administration (FDA), following the submission in March 2024.
About OMLYCLO® (CT-P39, biosimilar omalizumab)
Omlyclo® is the first European Commission (EC) approved anti-IgE antibody biosimilar referencing Xolair® (omalizumab). In the EU, Omlyclo® is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP).
About Celltrion
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma® and Yuflyma®, FDA approval for Zymfentra™, and EC approval for Remsima® SC. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Trademark
Xolair® is a registered trademark of Novartis AG.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521556727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Selected by Investec to Modernize Global Travel Program12.10.2026 10:00:00 CEST | Press release
Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Investec, a leading international bank and wealth manager, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009977645/en/ Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program “As Investec continues its digital transformation, we’re excited to partner with an AI-first travel platform to increase adoption and improve operational efficiency,” said Lyndon Subroyen, Investec Group Chief Technology and Operating Officer. As a dual-listed company in the United Kingdom and South Africa, Investec sought a partner to consolidate its travel operations, reduce administrative work, and improve the booking experience for its workforce. Inve
Opensignal Launches World’s First Interactive Map of Satellite-to-Smartphone D2D Connections12.10.2026 10:00:00 CEST | Press release
Provides Independent, Real-World Global View of Direct-to-Device Activity Opensignal, a global independent consumer connectivity analytics and insights company, today launched the Opensignal D2D Satellite Map, the world’s first interactive, real-world depiction of where direct-to-device (D2D) satellite connections with smartphones are happening across the globe. Every point on the map, which will be updated monthly, represents a location where smartphones have connected to a D2D service since January 2026, extracted from Opensignal’s billions of real-world measurements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261011884935/en/ Opensignal D2D Satellite Map “D2D is reshaping who can deliver mobile coverage, and where, because the phone in your pocket can now reach a satellite directly. Until now, the industry has had to make decisions without knowing where momentum and adoption are real,” said Mike Sandy, President, Mark
Demand for Tech Services in Europe Continues to Surge, Led by AI-Driven Infrastructure Spending in Q3: ISG Index™12.10.2026 10:00:00 CEST | Press release
Combined market up 56%, as infrastructure spend more than doublesManaged services up 12%, as enterprises look for savings to fund AI Surging AI demand propelled Europe’s technology services market to a new high in the third quarter, as infrastructure spending more than doubled and traditional managed services grew by double digits, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, finds. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based infrastructure and software services) soared 56 percent—its fastest growth in eight years—to US $14.9 billion. It was the fourth straight quarter that combined ACV growth has exceeded 20 percent, averaging 39 percent in that span. “The European market is absolutely roaring right now,” said
Carta Secures Authorization to Operate as Fund Administrator and Transfer Agent in Luxembourg12.10.2026 10:00:00 CEST | Press release
The connected platform for private capital adds licensed fund administration and transfer agency to an ERP suite built for Luxembourg fund managers Carta, the connected platform and AI-native ecosystem for private capital, today announced it has received authorization to operate as a fully-licensed Specialised Professional of the Financial Sector (PSF) under the supervision of the CSSF (Commission de Surveillance du Secteur Financier) in Luxembourg. The authorization covers five statutory functions — registrar agent, corporate domiciliation agent, company incorporation and management services, administrative agent of the financial sector, and client communication agent — adding licensed fund administration and transfer agency directly to a platform already serving Luxembourg fund managers. Luxembourg is the second-largest fund domicile in the world, home to approximately 5,000 alternative investment fund entities managing over €1 trillion in assets. It is also the preferred jurisdictio
CIG to Showcase How Next-Generation Broadband Is Driving More Value with PON, Wi-Fi, Optics, and Edge AI at Network X 2026, Booth C4.12.10.2026 09:11:00 CEST | Press release
From a full line of Wi‑Fi 8 Products to industrial Edge AI, CIG will demonstrate technologies designed to create more value across the network Cambridge Industries Group (CIG), a global leader in broadband and optical connectivity technologies, will showcase its latest broadband, optical, and Edge AI platform innovation at Network X 2026, October 13-15 in Vienna. The exhibit will focus on a practical challenge for network operators: how to increase capacity while improving the experience. CIG’s broadband showcase will span the network from fiber access to the connected home. Visitors will see live demonstrations of Wi-Fi 8 capabilities in an XGS-PON gateway, previewing CIG’s approach to next-generation Wi-Fi: greater flexibility in platform design and more dependable performance in real-world subscriber environments. CIG will also demonstrate its prplWare 4.2.1-certified Wi-Fi 7 device. CIG will also showcase the AIU-100 Edge AI controller, initially focused on manufacturing applicatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom